Komori
Governance3002GUNZE LIMITEDMaterials and Chemicals

GUNZE Integrated Report 2026_05

It disclosed fiscal 2025 results and financial condition, business segment information, and non-financial indicators. From fiscal 2023, the Medical Business has been presented as a separate reporting segment, independent from the Functional Solutions Business.

Worth reading
46Recurring
Scored from 1 of 5 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Governance structure

Controlling shareholder
No statement was found that there is no controlling shareholder or parent company.

When one company holds most of the voting rights, its wishes are more likely to prevail in management. How the interests of minority shareholders are protected is a key issue.

Changes this time

From fiscal 2023, the Medical Business, which had been included in the Functional Solutions segment, was presented as a separate Medical segment.

Governance structure
ItemDetails
Controlling shareholderNo statement was found that there is no controlling shareholder or parent company.
Changes this timeFrom fiscal 2023, the Medical Business, which had been included in the Functional Solutions segment, was presented as a separate Medical segment.
Items this document does not state (6)
Corporate Governance StructureNumber of directorsNumber of independent officersCommitteePolicy on cross-shareholdingsTakeover defenses

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

No reason was given for presenting the Medical Business as a separate segment. Factors cited for fluctuations in performance included the winding down of the electronic components business, lower overseas sales in the plastic films field, lower apparel sales, inventory valuation losses, and sluggish sales in China.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
GUNZE Integrated Report 2026_05 | GUNZE LIMITED (3002) timely disclosure | Komori